Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
C Visco,Y Li,Z Y Xu-Monette,R N Miranda,T M Green,Y Li,A Tzankov,W Wen,W-m Liu,B S Kahl,E S G d'Amore,S Montes-Moreno,K Dybkær,A Chiu,W Tam,A Orazi,Y Zu,G Bhagat,J N Winter,H-Y Wang,S O'Neill,C H Dunphy,E D Hsi,X F Zhao,R S Go,W W L Choi,F Zhou,M Czader,J Tong,X Zhao,J H van Krieken,Q Huang,W Ai,J Etzell,M Ponzoni,A J M Ferreri,M A Piris,M B Møller,C E Bueso-Ramos,L J Medeiros,L Wu,K H Young
DOI: https://doi.org/10.1038/leu.2012.83
2012-03-22
Leukemia
Abstract:Gene expression profiling (GEP) has stratified diffuse large B-cell lymphoma (DLBCL) into molecular subgroups that correspond to different stages of lymphocyte development–namely germinal center B-cell like and activated B-cell like. This classification has prognostic significance, but GEP is expensive and not readily applicable into daily practice, which has lead to immunohistochemical algorithms proposed as a surrogate for GEP analysis. We assembled tissue microarrays from 475 de novo DLBCL patients who were treated with rituximab-CHOP chemotherapy. All cases were successfully profiled by GEP on formalin-fixed, paraffin-embedded tissue samples. Sections were stained with antibodies reactive with CD10, GCET1, FOXP1, MUM1 and BCL6 and cases were classified following a rationale of sequential steps of differentiation of B cells. Cutoffs for each marker were obtained using receiver-operating characteristic curves, obviating the need for any arbitrary method. An algorithm based on the expression of CD10, FOXP1 and BCL6 was developed that had a simpler structure than other recently proposed algorithms and 92.6% concordance with GEP. In multivariate analysis, both the International Prognostic Index and our proposed algorithm were significant independent predictors of progression-free and overall survival. In conclusion, this algorithm effectively predicts prognosis of DLBCL patients matching GEP subgroups in the era of rituximab therapy.
oncology,hematology